CMS Rule on Pharma Patient-Assistance Programs Could Cut Back on Aid
A rule slated to take effect January 1, 2023 would reverse CMS' long held position that manufacturer-provided assistance given to patients is excluded from best price and average manufacturer price calculation for prescription drugs. The rule change could potentially result in increased patient out-of-pocket costs for drugs and pharma companies being on the hook for ensuring they know exactly where their assistance is going.